The therapeutic effect was associated with increased percentages of CD8+ T cells at the tumor site, indicating that other subsets of T cells, including CD4+ T cells and Tregs, may have limited roles during CTLA-4 blocking antibody cancer therapy. The gene discussed is CD8A; the disease is cancer.